Curated News
By: NewsRamp Editorial Staff
February 18, 2026

Silo Pharma Secures Key Japanese Patent for PTSD Treatment SPC-15

Original Source

TLDR

  • Silo Pharma's Japan patent allowance for SPC-15 strengthens its intellectual property edge in stress-modulating therapeutics within a key international market.
  • The Japan Patent Office issued a Notice of Allowance for Silo Pharma's patent application covering SPC-15, an intranasal therapeutic for PTSD, with composition and method claims.
  • Silo Pharma's patent progress for PTSD treatment SPC-15 advances potential relief for stress-induced psychiatric disorders, improving mental health outcomes.
  • Silo Pharma's novel intranasal PTSD treatment SPC-15 gains patent allowance in Japan, expanding its portfolio of stress-modulating therapeutics.

Impact - Why it Matters

This patent allowance represents a crucial step in validating Silo Pharma's innovative approach to mental health treatment, particularly for PTSD—a condition affecting millions globally with limited effective pharmaceutical options. The Japanese market approval signals international recognition of their intranasal delivery technology, which could revolutionize how stress-related disorders are treated by potentially offering faster-acting, more targeted therapy with fewer side effects than current oral medications. For patients, this development brings hope for more effective PTSD treatments that address the biological underpinnings of trauma response. For the healthcare industry, it demonstrates the growing legitimacy of novel drug delivery systems and psychedelic-inspired therapeutics in mainstream medicine. The expansion of intellectual property protection in a major pharmaceutical market like Japan also enhances Silo's valuation and partnership potential, potentially accelerating development timelines for much-needed mental health solutions.

Summary

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has achieved a significant milestone in its international expansion with the Japan Patent Office issuing a Notice of Allowance for its patent application covering lead asset SPC-15. This intranasal therapeutic targets post-traumatic stress disorder (PTSD) and is described in the application titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior." The allowance, which includes both composition and method claims, strengthens Silo's intellectual property portfolio in stress-modulating therapeutics within a key Asian market, with management emphasizing it protects the company's core scientific innovations ahead of formal patent grant. This development is particularly notable as Silo focuses on novel formulations and drug delivery systems for both traditional therapeutics and emerging psychedelic treatments.

The company's therapeutic pipeline addresses underserved conditions including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Beyond SPC-15 for PTSD, Silo's portfolio includes SP-26 for fibromyalgia and chronic pain, along with preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company conducts its research in collaboration with leading universities and laboratories, positioning itself at the intersection of biotechnology innovation and patient care. For investors seeking the latest updates, the company maintains a newsroom at https://ibn.fm/SILO, while the full press release can be accessed at https://ibn.fm/UB47M, providing comprehensive details about this patent development.

This announcement was distributed through BioMedWire ("BMW"), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on biotechnology, biomedical sciences, and life sciences sectors. BMW provides extensive distribution through wire solutions, article syndication to 5,000+ outlets, enhanced press release features, social media distribution to millions of followers, and tailored corporate communications solutions. The platform, which can be visited at https://www.BioMedWire.com, serves both private and public companies seeking to reach investors, influencers, consumers, and journalists in today's information-saturated market. As a diversified company that also maintains a cryptocurrency treasury, Silo Pharma represents an intriguing convergence of biopharmaceutical innovation and modern financial strategy, with its corporate information available at silopharma.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma Secures Key Japanese Patent for PTSD Treatment SPC-15

blockchain registration record for this content.